PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202073	4-((3-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-3-oxopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2353492-69-8	CRBN	ALK	Inquiry
Molecular Weight: 897.37 Molecular Formula: C44H50ClN10O7P Density: 1.46±0.1 g/cm3 Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
	BPL-202074	4-((4-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2353492-70-1	CRBN	ALK	Inquiry
Molecular Weight: 911.40 Molecular Formula: C45H52ClN10O7P Density: 1.45±0.1 g/cm3 Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
	BPL-202075	4-((5-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-5-oxopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2353492-76-7	CRBN	ALK	Inquiry
Molecular Weight: 925.43 Molecular Formula: C46H54ClN10O7P Density: 1.43±0.1 g/cm3 Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
	BPL-202076	4-((6-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-6-oxohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2353492-77-8	CRBN	ALK	Inquiry
Molecular Weight: 939.46 Molecular Formula: C47H56ClN10O7P Density: 1.42±0.1 g/cm3 Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
	BPL-202077	4-((7-(4-(1-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2353492-78-9	CRBN	ALK	Inquiry
Molecular Weight: 953.48 Molecular Formula: C48H58ClN10O7P Density: 1.41±0.1 g/cm3 Description: It is a brigatinib degrader with destroying metastasis-related oncoproteins and a reshuffling kinome profile.
	BPL-202078	(E)-5-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pentanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 892.35 Molecular Formula: C44H43ClFN11O7 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202079	(E)-8-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)octanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 934.43 Molecular Formula: C47H49ClFN11O7 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202080	(E)-9-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nonanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 948.46 Molecular Formula: C48H51ClFN11O7 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202081	(E)-10-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)decanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 962.48 Molecular Formula: C49H53ClFN11O7 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202082	(E)-11-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)undecanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 976.51 Molecular Formula: C50H55ClFN11O7 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202083	(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 938.37 Molecular Formula: C45H45ClFN11O9 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202084	(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((1-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 982.43 Molecular Formula: C47H49ClFN11O10 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202085	(E)-17-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-(4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaheptadecanamide		CRBN	EGFR e19d	Inquiry
Molecular Weight: 1070.53 Molecular Formula: C51H57ClFN11O12 Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202086	(2S,4R)-1-((S)-2-(5-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1049.68 Molecular Formula: C53H62ClFN12O6S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202087	(2S,4R)-1-((S)-2-(8-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1091.76 Molecular Formula: C56H68ClFN12O6S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202088	(2S,4R)-1-((S)-2-(9-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)nonanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1105.78 Molecular Formula: C57H70ClFN12O6S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202089	(2S,4R)-1-((S)-2-(10-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)decanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1119.81 Molecular Formula: C58H72ClFN12O6S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202090	(2S,4R)-1-((S)-2-(11-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1133.84 Molecular Formula: C59H74ClFN12O6S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202091	(2S,4R)-1-((S)-2-(2-(2-(2-(4-(((4-((3-Chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1095.69 Molecular Formula: C54H64ClFN12O8S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
	BPL-202092	(2S,4R)-1-((S)-2-(tert-Butyl)-20-(4-(((4-((3-chloro-4-fluorophenyl)amino)-6-((E)-4-(piperidin-1-yl)but-2-enamido)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide		VHL	EGFR e19d	Inquiry
Molecular Weight: 1227.86 Molecular Formula: C60H76ClFN12O11S Description: It is a novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.